Autonomix Medical's CEO will present at H.C. Wainwright’s conference, discussing innovative nervous system diagnostic technologies.
Quiver AI Summary
Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company focused on advancing diagnostic and treatment technologies for nervous system diseases, announced that CEO Brad Hauser will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. The company will also hold in-person one-on-one meetings for registered investors. A video webcast of Hauser's presentation will be available on-demand starting September 8, accessible for 90 days. Autonomix is developing a novel catheter-based microchip sensing array designed to improve the detection of neural signals, initially targeting pain management, particularly for pancreatic cancer, while also exploring broader applications in various medical fields. The technology is still investigational and not yet approved for marketing in the U.S.
Potential Positives
- Autonomix Medical is set to present at the H.C. Wainwright 27th Annual Global Investment Conference, an important event for investor outreach and visibility.
- The company's innovative technology featuring a catheter-based microchip sensing array aims to significantly improve the diagnosis and treatment of diseases involving the nervous system, showcasing its potential to revolutionize healthcare in this area.
- Autonomix's initial trials for treating pain linked to pancreatic cancer highlight the company's commitment to addressing serious health issues that currently lack reliable solutions, potentially attracting interest from investors and stakeholders.
Potential Negatives
- The company's technology is still investigational and has not yet been cleared for marketing in the United States, indicating potential regulatory hurdles and delays in commercialization.
- The focus on a single application (treatment of pain associated with pancreatic cancer) may raise concerns regarding the diversification and robustness of the company's product pipeline.
- The announcement of participation in an investor conference might imply a need for investor engagement, potentially signaling challenges in generating market interest or confidence in the company's progress.
FAQ
When is Brad Hauser presenting at the conference?
Brad Hauser will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025.
Where can I find the video webcast of the presentation?
The video webcast will be available on-demand starting September 8, 2025, on the Company’s website in the Events section.
What is Autonomix Medical focused on?
Autonomix Medical focuses on advancing technologies for diagnosing and treating diseases involving the nervous system.
What type of technology does Autonomix Medical develop?
Autonomix develops catheter-based microchip sensing arrays for detecting neural signals with high sensitivity.
What diseases is Autonomix Medical initially targeting?
The company is initially targeting pain management, focusing on pancreatic cancer and other potential indications.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AMIX Analyst Ratings
Wall Street analysts have issued reports on $AMIX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Maxim Group issued a "Buy" rating on 04/29/2025
To track analyst ratings and price targets for $AMIX, check out Quiver Quantitative's $AMIX forecast page.
Full Release
THE WOODLANDS, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix will present at the H.C. Wainwright 27 th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website .
A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 8, 2025, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company’s website ( autonomix.com ). The webcast replay will be archived for 90 days following the event.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X , LinkedIn , Instagram and Facebook .
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
[email protected]
